EN PL
CASE REPORT
Statin-induced autoimmune necrotizing myositis
 
More details
Hide details
 
Submission date: 2015-10-13
 
 
Final revision date: 2015-12-15
 
 
Acceptance date: 2016-01-12
 
 
Online publication date: 2016-02-11
 
 
Publication date: 2016-02-15
 
 
Reumatologia 2015;53(6):341-344
 
KEYWORDS
TOPICS
ABSTRACT
Myositides comprise a large group of disorders involving limb muscle weakness. In differential diagnosis we have to consider idiopathic myositides, myositides associated with other diseases, and those induced by external factors, e.g. drug-induced. Statins are commonly used drugs, but many patients experience a broad spectrum of adverse effects including symptoms from skeletal muscle. Physicians should pay special attention to patients reporting muscle weakness lasting longer than 12 weeks, despite statin withdrawal, as well as other symptoms: dysphagia, disturbed grip function, elevated creatinine kinase (CK) levels and abnormal electromyography.
The reported case deals with the problem of differential diagnosis of drug-induced muscle injury, polymyositis with a recently reported myopathy – statin-induced autoimmune necrotizing myositis, related to anti-HMGCR antibodies.
REFERENCES (25)
1.
Zwolińska G, Bodzioch M, Drabczyk R. Choroby układu nerwowo-mięśniowego. In: Choroby wewnętrzne. Szczeklik A, Gajewski P (eds.). Medycyna Praktyczna, Kraków 2011; 2023.
 
2.
Albayda J, Christopher-Stine L. Identifying statin-associated autoimmune necrotizing myopathy. Cleve Clin J Med 2014; 81: 736-741.
 
3.
Majdan M. Zapalenie wielomięśniowe i skórno-mięśniowe. In: Postępy reumatologii klinicznej. Zimmermann-Górska I (ed.). Wyd. Lekarskie PZWL, Warszawa 2014; 213-227.
 
4.
Majdan M. Dylematy diagnostyczno-terapeutyczne. PM/DM czy groźna, postatynowa miopatia? Interdyscyplinarne Oblicza Reumatologii 2015; 2: 4-6.
 
5.
Preuße C, Goebel HH, Held J, et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 2012; 181: 2161-2171.
 
6.
Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Reum 2012; 64: 4087-4093.
 
7.
Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylgutaryl-coenzym A reductase autoantibodies: an observational study in Japan. Medicine 2015; 94: e416.
 
8.
Kanth R, Shah MS, Flores RM. Statin-associated polymyositis following omeprazole treatment. Clin Med Res 2013; 11: 91-95.
 
9.
Mohassel P, Mammen AL. The spectrum of statin myopathy. Curr Opin Rheumatol 2013; 25: 747-752.
 
10.
Fulcher J, Keech A. The case for more intensive use of statins. Ther Adv Chron Dis 2012; 3: 201-210.
 
11.
Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc 2006; 46: 479-490.
 
12.
Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis: Statin-associated IMNM. Nat Rev Neurol 2011; 7: 343-354.
 
13.
Del Grande M, Christopher-Stine L. Expanding our understanding of statin myopathy. When it’s autoimmune? Int J Clin Rheumatol 2012; 7: 243-246.
 
14.
Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharm 2008; 8: 333-338.
 
15.
Mammen AL, Pak K, Williams EK, et al. Anti-HMG-CoA reductase antibodies are rare in statin users, including those with self-limited musculosceletal side-effects. Arthritis Care Res (Hoboken) 2012; 64: 269-272.
 
16.
Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62: 2757-2766.
 
17.
Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with antiHMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2015; 2: e124.
 
18.
Musset L, Miyara M, Benveniste O, et al. Analysis of autoantibodies to 3-hydroxy-3-methylgutaryl-coenzym A reductase using different technologies. J Immunol Res 2014; 2014: 405956.
 
19.
Ramanathan S, Langguth D, Hardy TA, et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm 2015; 2: e96.
 
20.
Lundberg IE, Vencovsky J, Alexanderson H. Therapy of myositis: biological and physical. Curr Opin Rheumatol 2014; 26: 704-711.
 
21.
Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002; 90 (suppl 109): 50K-60K.
 
22.
Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB 1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012; 64: 1233-1237.
 
23.
Bukhari M. Drug-induced rheumatic diseases. Curr Opin Rheumatol 2012; 24: 182-186.
 
24.
Yongpeng Ge, Xin Lu, Qinglin Peng, et al. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One 2015; 10: e0141616.
 
25.
Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009; 181: E11-E18.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top